A phase I study of MK-5108, an oral aurora A kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

BACKGROUND: MK-5108 is a potent/highly selective Aurora A kinase inhibitor. METHODS: A randomized Phase I study of MK-5108, administered p.o. BID Q12h on days 1–2 in 14–21 day cycles either alone (MT; Panel1/n=18; 200 to 1800 mg) or in combination (CT; Panel2/n=17; 100 to 225 mg) with IV docetaxel 6...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Invest New Drugs
Prif Awduron: Amin, Manik, Minton, Susan E., LoRusso, Patricia M., Krishnamurthi, Smitha S., Pickett, Cheryl A., Lunceford, Jared, Hille, Darcy, Mauro, David, Stein, Mark N., Wang-Gillam, Andrea, Trull, Lauren, Lockhart, A. Craig
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4806784/
https://ncbi.nlm.nih.gov/pubmed/26620496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0306-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg